Abstract:Hexameric structure formation through packing of three C-terminal helices and an N-terminal trimeric coiled-coil core has been proposed as a general mechanism of class I enveloped virus entry. In this process, the C-terminal helical repeat (HR2) region of viral membrane fusion proteins becomes transiently exposed and accessible to N-terminal helical repeat (HR1) trimer-based fusion inhibitors. Herein, we describe a mimetic of the HIV-1 gp41 HR1 trimer, N3G, as a promising therapeutic against HIV-1 infection. Surprisingly, we found that in addition to protection against HIV-1 infection, N3G was also highly effective in inhibiting infection of human β-coronaviruses, including MERS-CoV, HCoV-OC43, and SARS-CoV-2, possibly by binding the HR2 region in the spike protein of β-coronaviruses to block their hexameric structure formation. These studies demonstrate the potential utility of anti-HIV-1 HR1 peptides in inhibiting human β-coronavirus infection. Moreover, this strategy could be extended to the design of broad-spectrum antivirals based on the supercoiling structure of peptides.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00258?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00258</a>.Summary of the SVA results; biophysical properties of the designed peptides; HPLC method used for the purification of peptide compounds; HPLC method used for the analysis of peptide compounds; evidence that both N3G and EK1 are effective against SARS-CoV-2 infection; CD spectra of the complex formed between N3G and SARS-CoV-2 HR2P; sequence similarity between the HR2 domain of MERS-CoV, OC43, or SARS-CoV-2 and that of HIV-1; inhibitory activity of peptides on pseudotyped SARS-CoV infection; and MALDI-TOF-MS and analytical HPLC of designed peptides (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00258/suppl_file/jm1c00258_si_002.pdf">PDF</a>)Molecular formula strings of all compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00258/suppl_file/jm1c00258_si_003.csv">CSV</a>)This article has not yet been cited by other publications.

Dimerized fusion inhibitor peptides targeting the HR1-HR2 interaction of SARS-CoV-2

Designed peptides as potential fusion inhibitors against SARA-CoV-2 coronavirus infection

Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.

An HR2-Mimicking Sulfonyl-γ-AApeptide is a Potent Pan-coronavirus Fusion Inhibitor with Strong Blood–Brain Barrier Permeability, Long Half-Life, and Promising Oral Bioavailability

A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain Against SARS-CoV-2 and Its Variants of Concern

Investigating vulnerability of the conserved SARS-CoV-2 spike's heptad repeat 2 as target for fusion inhibitors using chimeric miniproteins

Stapled Peptides Targeting SARS-CoV-2 Spike Protein HR1 Inhibit the Fusion of Virus to Its Cell Receptor

Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus.

Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains

Bivalent HIV-1 fusion inhibitors based on peptidomimetics

Viral Prefusion Targeting Using Entry Inhibitor Peptides: The Case of SARS-CoV-2 and Influenza A virus

Why Are HIV-1 Fusion Inhibitors Not Effective Against SARS-CoV? Biophysical Evaluation of Molecular Interactions

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Empowering SARS‐CoV‐2 variant neutralization with a bifunctional antibody engineered with tandem heptad repeat 2 peptides

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Characterization of the Heptad Repeat Regions, HR1 and HR2, and Design of a Fusion Core Structure Model of the Spike Protein from Severe Acute Respiratory Syndrome (SARS) Coronavirus.

Fusion Core Structure of the Severe Acute Respiratory Syndrome Coronavirus (Sars-Cov): in Search of Potent Sars-Cov Entry Inhibitors

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants

Design of MERS-CoV entry inhibitory short peptides based on helix-stabilizing strategies

The Role of Palmitic Acid Conjugation

Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human β-Coronavirus Infection